000			01675 a2200481 4500
005			20250513232933.0
264		0	_c20010510
008			200105s 0 0 eng d
022			_a0022-1899
024	7		_a10.1086/319284 _2doi
040			_aNLM _beng _cNLM
100	1		_aNagashima, K A
245	0	0	_aHuman immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. _h[electronic resource]
260			_bThe Journal of infectious diseases _cApr 2001
300			_a1121-5 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAnimals
650	0	4	_aAnti-HIV Agents _xpharmacology
650	0	4	_aCD4 Immunoadhesins _xpharmacology
650	0	4	_aCHO Cells
650	0	4	_aCell Fusion
650	0	4	_aCell Line
650	0	4	_aCricetinae
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Synergism
650	0	4	_aEnfuvirtide
650	0	4	_aEukaryotic Cells _xpathology
650	0	4	_aHIV Envelope Protein gp41 _xpharmacology
650	0	4	_aHIV Infections _xvirology
650	0	4	_aHIV-1 _xdrug effects
650	0	4	_aHeLa Cells
650	0	4	_aHumans
650	0	4	_aPeptide Fragments _xpharmacology
650	0	4	_aT-Lymphocytes _xvirology
650	0	4	_aVirus Replication _xdrug effects
700	1		_aThompson, D A
700	1		_aRosenfield, S I
700	1		_aMaddon, P J
700	1		_aDragic, T
700	1		_aOlson, W C
773	0		_tThe Journal of infectious diseases _gvol. 183 _gno. 7 _gp. 1121-5
856	4	0	_uhttps://doi.org/10.1086/319284 _zAvailable from publisher's website
999			_c11175149 _d11175149